Hillgene

Hillgene Biopharma is a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy. Headquartered in Suzhou, China, with GMP facilities in Suzhou and Shenzhen—and expanding into North Carolina, USA—the company offers end‑to‑end support for CAR‑T, TCR‑T, CAR‑NK, and stem cell therapies.

Their expertise spans nucleic acid (plasmid/mRNA) production, serum‑free suspension culture, fully closed-cell processing workflows, lentiviral vector manufacturing, and rigorous QC testing With over 6 successful IND submissions and more than 200 clinically-prepared cell therapy batches produced within an 18,000 m² GMP facility, Hillgene is committed to accelerating development timelines and helping more life-changing therapies reach patients faster.